Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
Korean Journal of Clinical Oncology
;
(2): 108-115, 2018.
Article
in English
| WPRIM
| ID: wpr-788037
ABSTRACT
PURPOSE:
This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival. Secondary endpoints included cardiac safety, tolerability, and overall survival.METHODS:
The study included 60 non-metastatic HER2-positive breast cancer patients. All study patients underwent surgery, received adjuvant chemotherapy, radiotherapy and hormonal therapy if indicated. Thirty patients were randomized in each group. Group I patients received adjuvant trastuzumab for 12 months, while group II patients received adjuvant trastuzumab for 9 months. Patients were assessed by clinical examination and Echocardiography during treatment.RESULTS:
After median follow-up of 12 months, 90% of the patients in group I were disease free and 83.3% of patients in group II were disease free (P=0.402). All studied population in both groups I and II were alive at the end of the 1-year follow-up period after the completion of adjuvant trastuzumab treatment thus overall survival is 100%.CONCLUSION:
Trastuzumab is tolerable and its side effects are reversible. Nine months of adjuvant trastuzumab treatment is more cost effective than the standard 12 months.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Radiotherapy
/
Breast
/
Breast Neoplasms
/
Echocardiography
/
Follow-Up Studies
/
Chemotherapy, Adjuvant
/
Disease-Free Survival
/
Epidermal Growth Factor
/
Trastuzumab
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Korean Journal of Clinical Oncology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS